Evolent Health/$EVH
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Evolent Health
Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The solutions provided by the company includes: Oncology, Cardiology, Musculoskeletal, Administrative Services, Advanced Illness, Genetic Testing, Physical Medicine, Radiology, and Surgical Management.
- Ticker
- $EVH
- Sector
- Health
- Primary listing
- NYSE
- Employees
- 4,200
- Headquarters
- Arlington, United States
- Website
- www.evolent.com
Evolent Health Metrics
BasicAdvanced
$486M
-
-$4.54
1.02
-
Price and volume
Market cap
$486M
Beta
1.02
52-week high
$6.89
52-week low
$2.10
Average daily volume
1.9M
Financial strength
Current ratio
1.239
Quick ratio
1.146
Long term debt to equity
2.528
Total debt to equity
2.532
Interest coverage (TTM)
-0.40%
Profitability
EBITDA (TTM)
61.037
Gross margin (TTM)
17.25%
Net profit margin (TTM)
-24.08%
Operating margin (TTM)
-1.33%
Effective tax rate (TTM)
-0.57%
Revenue per employee (TTM)
$500,000
Management effectiveness
Return on assets (TTM)
-0.78%
Return on equity (TTM)
-66.97%
Valuation
Price to revenue (TTM)
0.231
Price to book
1.26
Price to tangible book (TTM)
-0.51
Price to free cash flow (TTM)
23.026
Free cash flow yield (TTM)
4.34%
Free cash flow per share (TTM)
0.187
Growth
Revenue change (TTM)
-4.50%
Earnings per share change (TTM)
182.72%
3-year revenue growth (CAGR)
8.72%
10-year revenue growth (CAGR)
26.98%
3-year earnings per share growth (CAGR)
82.89%
10-year earnings per share growth (CAGR)
2.03%
What the Analysts think about Evolent Health
Analyst ratings (Buy, Hold, Sell) for Evolent Health stock.
Analyst projections of the future price of Evolent Health stock.
Bulls say / Bears say
Evolent expects a new oncology partnership covering 1.5 million lives to add about $300 million in annualised revenue once it launches, giving the company a sizeable source of growth. It expects the contract to start by December 2026, subject to regulatory approval. (Evolent Health)
A Health Care Transformation Task Force case study found that Evolent’s oncology model raised adherence to clinical pathways by about 30%, cut use of low-value regimens by 20% and reduced hospital and emergency visits by 40%. These reported results could help support demand for its complex-care services. (Health Care Transformation Task Force)
Evolent says its AI platform now handles more than a third of authorisations requiring manual clinical review, with auto-approval rates rising by up to 20 percentage points for some clients. If those efficiency gains scale while maintaining clinical quality, they could help contain operating costs. (The Motley Fool)
Profitability has not kept pace with revenue: Q2 adjusted EBITDA margin fell to 4.3% from 8.5% a year earlier, while the medical expense ratio rose to 95.3% from 80.0%. Persistently high care costs could limit the benefit of further growth. (Evolent Health)
The balance sheet and cash generation leave limited room for setbacks: Evolent used $10.3 million of operating cash in the first half and reported $808.3 million of net debt at the end of Q2. It also faces about $60 million of annual cash interest and is working on its 2029 maturities. (The Motley Fool)
Management expects Medicaid and client-specific membership losses to remain headwinds in 2027, alongside further exchange membership attrition. Those declines could offset new contract launches and make the growth outlook harder to deliver. (Evolent Health, The Motley Fool)
Data summarised monthly by Lightyear AI. Last updated on 27 Oct 2026.
Evolent Health Financial Performance
Revenues and expenses
Evolent Health Earnings Performance
Company profitability
Upcoming events
No upcoming events
Evolent Health News
AllArticlesVideos
Funds containing Evolent Health
Fund name | Fund size | $EVH weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 0.04% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.04% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.04% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.02% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.02% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.